Latest news with #MedLeafTherapeutics
Yahoo
7 hours ago
- Business
- Yahoo
Aurora Cannabis says ‘second instance of misinformation' posted on Investing.com
Aurora Cannabis (ACB) announced that it has become aware of 'a second instance of misinformation' posted on news website On June 18, Aurora advised the market that an article posted on incorrectly stated that Aurora had agreed to acquire New Zealand-based MedLeaf Therapeutics. Later in the day on June 18, a second article was posted on that incorrectly states that Aurora has entered into a strategic partnership with MediPharm GmbH for distribution of medical cannabis in Germany and other EU markets. 'The company categorically denies both articles. Aurora has not entered into any such agreements, has had no discussions with MedLeaf Therapeutics or MediPharm GmbH with respect to any business combination transaction or strategic partnership, and has not made any statements or filed any information pertaining to any such transactions. The erroneous articles posted on state that they were generated 'with the support of AI' and reviewed by an editor. The company is launching an investigation into the genesis of these articles. In the meantime, Aurora confirms that it is not in possession of material non-public information and advises investors that should not be considered a credible source of information regarding the company. Any information regarding material corporate transactions will be announced directly by the company to the market as soon as it is appropriate to do so,' Aurora stated. Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>> See the top stocks recommended by analysts >> Read More on ACB: Disclaimer & DisclosureReport an Issue Aurora Cannabis Reports Record Revenue and Growth Aurora Cannabis Denies Acquisition Rumors of MedLeaf Therapeutics Aurora Cannabis denies acquisition of MedLeaf Therapeutics Morning Movers: Circle rises following regulatory framework for stablecoins Aurora Cannabis Achieves Record Revenue and EBITDA in Fiscal 2025 Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
The Market Online
a day ago
- Business
- The Market Online
Aurora Cannabis clears the air and denies MedLeaf acquisition news
Aurora Cannabis (TSX:ACB) issued a firm denial of recent misinformation circulating online regarding alleged acquisitions and strategic partnerships The company became aware of an article posted on a news website falsely claiming that Aurora had agreed to acquire New Zealand-based MedLeaf Therapeutics A second article incorrectly reported that Aurora had signed a partnership with MediPharm (TSX:LABS) distribute medical cannabis in Germany and other European Union markets Aurora Cannabis stock (TSX:ACB) last traded at C$6.40 Top Canadian global medical cannabis company Aurora Cannabis (TSX:ACB) has issued a firm denial of recent misinformation circulating online regarding alleged acquisitions and strategic partnerships. The company became aware of an article posted on a news website falsely claiming that Aurora had agreed to acquire New Zealand-based MedLeaf Therapeutics. Aurora categorically stated that it has not entered into any such agreement, has had no discussions with MedLeaf Therapeutics regarding a business combination, and has not released or filed any information suggesting such a transaction. Further compounding the issue, a second article published on June 18, 2025, by incorrectly reported that Aurora had signed a partnership with MediPharm (TSX:LABS) to distribute medical cannabis in Germany and other European Union markets (oof, that's awkward). Aurora has also denied this claim, stating unequivocally that no such agreement or discussions have taken place. Both articles, which claims were generated 'with the support of AI' and reviewed by an editor, have prompted Aurora to launch an internal investigation into the origin and dissemination of the misinformation. Aurora emphasized that it is not in possession of any material non-public information and reaffirmed its commitment to transparency. The company assured the market that any material corporate developments will be communicated directly and appropriately. The company urged investors to rely solely on official announcements and regulatory filings for accurate and up-to-date information. Aurora is a global cannabis company serving both the medical and consumer markets across Canada, Europe, Australia and South America. Its brand portfolio includes Drift, San Rafael '71, Daily Special, Tasty's, Being, Greybeard, MedReleaf, CanniMed, Aurora, Whistler Medical Marijuana Co., Pedanios, IndiMed and CraftPlant. Aurora Cannabis stock (TSX:ACB) last traded at C$6.40 and has risen 4.75 per cent since the year began, but has fallen 15.12 per cent since this time last year. Join the discussion: Find out what everybody's saying about this cannabis stock's expansion in Germany on the Aurora Cannabis Inc. Bullboard and check out Stockhouse's stock forums and message boards. The material provided in this article is for information only and should not be treated as investment advice. For full disclaimer information, please click here.
Yahoo
2 days ago
- Business
- Yahoo
Aurora Cannabis Denies News of Acquisition of MedLeaf Therapeutics
NASDAQ | TSX: ACB EDMONTON, AB, June 18, 2025 /PRNewswire/ - Aurora Cannabis Inc. (the "Company" or "Aurora") (NASDAQ: ACB) (TSX: ACB), a leading Canada-based global medical cannabis company, has become aware of misinformation posted on a news website, incorrectly stating that Aurora has agreed to acquire New Zealand based MedLeaf Therapeutics. The Company has not entered into any such agreement, has had no discussions with MedLeaf Therapeutics with respect to any business combination transaction, and has not made any statement or filed any information pertaining to any such transaction. Earlier today before market open, Aurora filed the Company's financial statements and management's discussion and analysis for the fourth quarter and fiscal year ending March 31, 2025. All information pertaining to these disclosures is available on the Company's website at and on SEDAR+ and EDGAR. About Aurora Cannabis Aurora is opening the world to cannabis, serving both the medical and consumer markets across Canada, Europe, Australia and New Zealand. Headquartered in Edmonton, Alberta, Aurora is a pioneer in global cannabis, dedicated to helping people improve their lives. The Company's adult-use brand portfolio includes Drift, San Rafael '71, Daily Special, Tasty's, Being and Greybeard. Medical cannabis brands include MedReleaf, CanniMed, Aurora and Whistler Medical Marijuana Co., as well as international brands, Pedanios, Bidiol, IndiMed and CraftPlant. Aurora also has a controlling interest in Bevo Farms Ltd., North America's leading supplier of propagated agricultural plants. Driven by science and innovation, and with a focus on high-quality cannabis products, Aurora's brands continue to break through as industry leaders in the medical, wellness and adult recreational markets wherever they are launched. Learn more at and follow us on X and LinkedIn. Aurora's common shares trade on the NASDAQ and TSX under the symbol "ACB". Forward Looking Information This news release includes statements containing certain "forward-looking information" within the meaning of applicable securities law ("forward-looking statements"). Forward-looking statements are frequently characterized by words such as "plan", "continue", "expect", "project", "intend", "believe", "anticipate", "estimate", "may", "will", "potential", "proposed" and other similar words, or statements that certain events or conditions "may" or "will" occur. These forward-looking statements are only predictions. Forward looking information or statements contained in this news release have been developed based on assumptions management considers to be reasonable. Material factors or assumptions involved in developing forward-looking statements include, without limitation, publicly available information from governmental sources as well as from market research and industry analysis and on assumptions based on data and knowledge of this industry which the Company believes to be reasonable. Forward-looking statements are subject to a variety of risks, uncertainties and other factors that management believes to be relevant and reasonable in the circumstances could cause actual events, results, level of activity, performance, prospects, opportunities or achievements to differ materially from those projected in the forward-looking statements. These risks include, but are not limited to, the magnitude and duration of potential new or increased tariffs imposed on goods imported from Canada into the United States; the ability to retain key personnel, the ability to continue investing in infrastructure to support growth, the ability to obtain financing on acceptable terms, the continued quality of our products, customer experience and retention, the development of third party government and non-government consumer sales channels, management's estimates of consumer demand in Canada and in jurisdictions where the Company exports, expectations of future results and expenses, the ability to expand and maintain distribution capabilities, the impact of competition, the general impact of financial market conditions, the yield from cannabis growing operations, product demand, changes in prices of required commodities, competition, and the possibility for changes in laws, rules, and regulations in the industry, epidemics, pandemics or other public health crises and other risks, uncertainties and factors set out under the heading "Risk Factors" in the Company's annual information form dated June 17, 2025 (the "AIF") and filed with Canadian securities regulators available on the Company's issuer profile on SEDAR+ at and filed with and available on the SEC's website at The Company cautions that the list of risks, uncertainties and other factors described in the AIF is not exhaustive and other factors could also adversely affect its results. Readers are urged to consider the risks, uncertainties and assumptions carefully in evaluating the forward-looking statements and are cautioned not to place undue reliance on such information. The Company is under no obligation, and expressly disclaims any intention or obligation, to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as expressly required by applicable securities law. View original content to download multimedia: SOURCE Aurora Cannabis Inc. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Cision Canada
2 days ago
- Business
- Cision Canada
Aurora Cannabis Denies News of Acquisition of MedLeaf Therapeutics
NASDAQ| TSX: ACB EDMONTON, AB, June 18, 2025 /CNW/ - Aurora Cannabis Inc. (the "Company" or "Aurora") (NASDAQ: ACB) (TSX: ACB), a leading Canada-based global medical cannabis company, has become aware of misinformation posted on a news website, incorrectly stating that Aurora has agreed to acquire New Zealand based MedLeaf Therapeutics. The Company has not entered into any such agreement, has had no discussions with MedLeaf Therapeutics with respect to any business combination transaction, and has not made any statement or filed any information pertaining to any such transaction. Earlier today before market open, Aurora filed the Company's financial statements and management's discussion and analysis for the fourth quarter and fiscal year ending March 31, 2025. All information pertaining to these disclosures is available on the Company's website at and on SEDAR+ and EDGAR. About Aurora Cannabis Aurora is opening the world to cannabis, serving both the medical and consumer markets across Canada, Europe, Australia and New Zealand. Headquartered in Edmonton, Alberta, Aurora is a pioneer in global cannabis, dedicated to helping people improve their lives. The Company's adult-use brand portfolio includes Drift, San Rafael '71, Daily Special, Tasty's, Being and Greybeard. Medical cannabis brands include MedReleaf, CanniMed, Aurora and Whistler Medical Marijuana Co., as well as international brands, Pedanios, Bidiol, IndiMed and CraftPlant. Aurora also has a controlling interest in Bevo Farms Ltd., North America's leading supplier of propagated agricultural plants. Driven by science and innovation, and with a focus on high-quality cannabis products, Aurora's brands continue to break through as industry leaders in the medical, wellness and adult recreational markets wherever they are launched. Learn more at and follow us on X and LinkedIn. Aurora's common shares trade on the NASDAQ and TSX under the symbol "ACB". Forward Looking Information This news release includes statements containing certain "forward-looking information" within the meaning of applicable securities law (" forward-looking statements"). Forward-looking statements are frequently characterized by words such as "plan", "continue", "expect", "project", "intend", "believe", "anticipate", "estimate", "may", "will", "potential", "proposed" and other similar words, or statements that certain events or conditions "may" or "will" occur. These forward-looking statements are only predictions. Forward looking information or statements contained in this news release have been developed based on assumptions management considers to be reasonable. Material factors or assumptions involved in developing forward-looking statements include, without limitation, publicly available information from governmental sources as well as from market research and industry analysis and on assumptions based on data and knowledge of this industry which the Company believes to be reasonable. Forward-looking statements are subject to a variety of risks, uncertainties and other factors that management believes to be relevant and reasonable in the circumstances could cause actual events, results, level of activity, performance, prospects, opportunities or achievements to differ materially from those projected in the forward-looking statements. These risks include, but are not limited to, the magnitude and duration of potential new or increased tariffs imposed on goods imported from Canada into the United States; the ability to retain key personnel, the ability to continue investing in infrastructure to support growth, the ability to obtain financing on acceptable terms, the continued quality of our products, customer experience and retention, the development of third party government and non-government consumer sales channels, management's estimates of consumer demand in Canada and in jurisdictions where the Company exports, expectations of future results and expenses, the ability to expand and maintain distribution capabilities, the impact of competition, the general impact of financial market conditions, the yield from cannabis growing operations, product demand, changes in prices of required commodities, competition, and the possibility for changes in laws, rules, and regulations in the industry, epidemics, pandemics or other public health crises and other risks, uncertainties and factors set out under the heading "Risk Factors" in the Company's annual information form dated June 17, 2025 (the "AIF") and filed with Canadian securities regulators available on the Company's issuer profile on SEDAR+ at and filed with and available on the SEC's website at The Company cautions that the list of risks, uncertainties and other factors described in the AIF is not exhaustive and other factors could also adversely affect its results. Readers are urged to consider the risks, uncertainties and assumptions carefully in evaluating the forward-looking statements and are cautioned not to place undue reliance on such information. The Company is under no obligation, and expressly disclaims any intention or obligation, to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as expressly required by applicable securities law.
